Magnetar Financial LLC bought a new position in Elevance Health, Inc. (NYSE:ELV – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,250 shares of the company’s stock, valued at approximately $648,000.
Several other hedge funds have also recently bought and sold shares of ELV. SeaCrest Wealth Management LLC raised its stake in Elevance Health by 4.3% during the fourth quarter. SeaCrest Wealth Management LLC now owns 2,310 shares of the company’s stock worth $1,109,000 after acquiring an additional 95 shares in the last quarter. Clear Harbor Asset Management LLC bought a new position in shares of Elevance Health in the fourth quarter valued at about $353,000. Global Retirement Partners LLC raised its holdings in shares of Elevance Health by 3.0% in the fourth quarter. Global Retirement Partners LLC now owns 3,313 shares of the company’s stock valued at $1,568,000 after buying an additional 98 shares during the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Elevance Health by 59.4% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 3,013 shares of the company’s stock valued at $1,421,000 after buying an additional 1,123 shares during the last quarter. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH raised its holdings in shares of Elevance Health by 3,888.6% in the fourth quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 18,587 shares of the company’s stock valued at $8,765,000 after buying an additional 18,121 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.
Elevance Health Stock Performance
ELV traded down $3.90 during trading hours on Monday, reaching $523.60. The company’s stock had a trading volume of 71,391 shares, compared to its average volume of 1,058,520. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.49 and a current ratio of 1.49. The company’s 50-day moving average is $530.22 and its 200-day moving average is $516.31. Elevance Health, Inc. has a 52 week low of $431.38 and a 52 week high of $555.35. The firm has a market cap of $121.42 billion, a PE ratio of 19.94, a price-to-earnings-growth ratio of 1.17 and a beta of 0.84.
Elevance Health Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Stockholders of record on Tuesday, September 10th will be issued a dividend of $1.63 per share. This represents a $6.52 annualized dividend and a dividend yield of 1.25%. The ex-dividend date is Tuesday, September 10th. Elevance Health’s dividend payout ratio (DPR) is currently 24.64%.
Analyst Ratings Changes
A number of research analysts recently issued reports on ELV shares. UBS Group lifted their price target on Elevance Health from $585.00 to $605.00 and gave the company a “buy” rating in a report on Friday, April 19th. Truist Financial boosted their price objective on Elevance Health from $600.00 to $620.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Mizuho boosted their target price on Elevance Health from $575.00 to $585.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Baird R W upgraded Elevance Health to a “strong-buy” rating in a research report on Thursday, May 30th. Finally, Morgan Stanley began coverage on Elevance Health in a research report on Monday, June 24th. They set an “overweight” rating and a $643.00 target price for the company. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $604.29.
View Our Latest Analysis on Elevance Health
Insider Transactions at Elevance Health
In other news, CEO Gail Boudreaux sold 34,000 shares of the stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $500.98, for a total transaction of $17,033,320.00. Following the sale, the chief executive officer now directly owns 126,709 shares of the company’s stock, valued at approximately $63,478,674.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Elevance Health news, Director Robert L. Dixon, Jr. sold 305 shares of the stock in a transaction dated Friday, July 19th. The stock was sold at an average price of $506.76, for a total value of $154,561.80. Following the completion of the transaction, the director now directly owns 9,721 shares in the company, valued at $4,926,213.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Gail Boudreaux sold 34,000 shares of the stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $500.98, for a total value of $17,033,320.00. Following the completion of the transaction, the chief executive officer now owns 126,709 shares of the company’s stock, valued at $63,478,674.82. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.
Elevance Health Company Profile
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Featured Stories
- Five stocks we like better than Elevance Health
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Nearly 100% Accurate Indicator Reveals Top Stocks to Buy
- Industrial Products Stocks Investing
- Time to Take a Bite of This Stock’s Enticing Value
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 4 Reasons to Buy This AI Leader After the Stock Split
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.